News

Belgian Growth Fund invests 15 million euros in Gilde Healthcare V, an investment fund based in the Netherlands that invests in fast-growing, innovative companies that enable better care at lower costs. With this, Belgian Growth Fund realises its fourth investment in six months, after previous investments in Smartfin Capital II, Fortino Capital II Growth and Sofindev V. In Belgium, Gilde Healthcare's portfolio includes the Walloon company Nyxoah, which develops innovative therapies against sleep apnea.

Gilde Healthcare is a specialist European investment company with EUR 1.4 billion under management in two separate fund strategies: venture & growth capital and private equity. Gilde Healthcare V, the new EUR 416 million venture & growth capital fund, participates in medical technology and new medicines. Target venture & growth companies are based in Europe and North America. Gilde Healthcare V is supported by a balanced mix of international investors, including banks, pension funds, government funds, foundations, family offices, entrepreneurs and Gilde partners. Royal Philips has joined Gilde Healthcare V as a corporate investor, continuing a long-term partnership.

Enabling health care at lower costs

Pieter van der Meer, Managing Partner of Gilde Healthcare, explains: "The healthcare landscape in Europe and the US is changing rapidly, driven by the need for more patient-centric care and more attention to value-driven care. With our new fund we will continue our strategy to invest in companies in the venture and growth phase that are developing new solutions to enable better healthcare outcomes at lower costs". An example of this is remote monitoring and home care of patients. "This is now more relevant than ever in the fight against COVID-19." According to Jan Alexander and Mireille Kielemoes of Belgian Growth Fund.